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Abstract: BACKGROUND AIMS It is not clear how rapid ascent to high altitude causes the gastroin-
testinal symptoms of acute mountain sickness (AMS). We assessed the incidence of endoscopic lesions
in the upper gastrointestinal tract in healthy mountaineers after rapid ascent to high altitude, their as-
sociation with symptoms, and their pathogenic mechanisms. METHODS In a prospective study, 25 moun-
taineers (10 female; mean age, 43.8y±9.5 y) underwent unsedated, transnasal esophago-gastroduodenoscopy
in Zurich (490 m) and then on 2 test days (days 2 and 4) at a high altitude laboratory in the Alps (Ca-
panna Regina Margherita, 4559 m). Symptoms were assessed using validated instruments for AMS (the
AMS-C and the Lake Louise scoring system) and visual analogue scales (0-100). Levels of mRNAs in
duodenal biopsies were measured by qPCR. RESULTS The follow-up endoscopy at high altitude was
performed in 19/25 patients on day 2 and in 23/25 patients on day 4. Frequency of endoscopic lesions
increased from 12% at baseline to 26.3% on day 2 and 60.9% on day 4 (P<0.001). The incidence of ulcer
disease increased from 0 at baseline to 10.5% on day 2 and 21.7% on day 4 (P=.014). Mucosal lesions
were associated with lower hunger scores (37.3 vs. 67.4 in patients without lesions; P=.012). Subjects
with peptic lesions had higher levels of HIF2A mRNA, which encodes a hypoxia-induced transcription
factor, and ICAM1 mRNA, which encodes an adhesion molecule, compared with subjects without lesions
(fold changes: 1.38 vs 0.63; P=.001 and 1.37 vs 0.66; P=.011). CONCLUSIONS In a prospective study
of 25 mountaineers, fast ascent to high altitude resulted in rapid onset of clinically meaningful mucosal
lesions and ulcer disease. Duodenal biopsies from these subjects had increased levels of HIF2A mRNA
and ICAM1 mRNA, which might contribute to formation of hypoxia-induced peptic lesions. Further
studies are needed of the mechanisms of this process.
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ABBREVIATIONS: 
AMS: acute mountain sickness 
AMS-C: acute mountain sickness score 
BMI: body mass index 
CRP: C-reactive protein 
EGD: esophagogastroduodenoscopy 
GI: gastrointestinal 
HAPE: high altitude pulmonary edema 
IBD: inflammatory bowel disease 
IQR: interquartile range 
LLSAS: Lake Louise acute mountain sickness score 
mRNA: messenger RNA 
NSAIDs: non-steroidal anti-inflammatory drugs 
O2 Hb: oxyhemoglobin  
pCO2: partial pressure of carbon dioxide 
pO2: partial pressure of oxygen 
PPI: proton pump inhibitor 
qPCR: quantitative polymerase-chain-reaction 
RNA: ribonucleic acid 
SD: standard deviation 
SpO2: oxygen saturation 

















Background & Aims: It is not clear how rapid ascent to high altitude causes the 
gastrointestinal symptoms of acute mountain sickness (AMS). We assessed the incidence of 
endoscopic lesions in the upper gastrointestinal tract in healthy mountaineers after rapid 
ascent to high altitude, their association with symptoms, and their pathogenic mechanisms. 
 
Methods: In a prospective study, 25 mountaineers (10 female; mean age, 43.8y±9.5 y) 
underwent unsedated, transnasal esophago-gastroduodenoscopy in Zurich (490 m) and then 
on 2 test days (days 2 and 4) at a high altitude laboratory in the Alps (Capanna Regina 
Margherita, 4559 m). Symptoms were assessed using validated instruments for AMS (the 
AMS-C and the Lake Louise scoring system) and visual analogue scales (0–100). Levels of 
mRNAs in duodenal biopsies were measured by qPCR. 
 
Results: The follow-up endoscopy at high altitude was performed in 19/25 patients on day 2 
and in 23/25 patients on day 4. Frequency of endoscopic lesions increased from 12% at 
baseline to 26.3% on day 2 and 60.9% on day 4 (P<0.001). The incidence of ulcer disease 
increased from 0 at baseline to 10.5% on day 2 and 21.7% on day 4 (P=.014). Mucosal lesions 
were associated with lower hunger scores (37.3 vs. 67.4 in patients without lesions; P=.012). 
Subjects with peptic lesions had higher levels of HIF2A mRNA, which encodes a hypoxia-
induced transcription factor, and ICAM1 mRNA, which encodes an adhesion molecule, 
compared with subjects without lesions (fold changes: 1.38 vs 0.63; P=.001 and 1.37 vs 0.66; 
P=.011).  
 
Conclusions: In a prospective study of 25 mountaineers, fast ascent to high altitude resulted 
in rapid onset of clinically meaningful mucosal lesions and ulcer disease. Duodenal biopsies 
from these subjects had increased levels of HIF2A mRNA and ICAM1 mRNA, which might 
contribute to formation of hypoxia-induced peptic lesions. This axis warrants further 
mechanistic studies. 
 
KEY WORDS:  EGD, stomach, intercellular adhesion molecule, endothelial PAS domain 
protein 1 
 
Need to Know 
 
Background: It is not clear how rapid ascent to high altitude causes the gastrointestinal 
symptoms of acute mountain sickness. 
 
Findings: In a prospective study of 25 mountaineers, we found that rapid ascent to high 
altitude (4559 m) resulted in mucosal lesions and ulcer disease. Duodenal biopsies from 
these subjects had increased levels of HIF2A mRNA and ICAM1 mRNA, which might 
contribute to formation of hypoxia-induced peptic lesions. 
 
Implications for patient care: Mountaineers should be careful to ascend too rapidly, to avoid 
peptic ulcer disease and damage to the intestinal mucosa. Similar mechanisms might 





















Rapid ascent to high altitude levels is a particular risk factor for the development of 
acute mountain sickness (AMS).1 Both, experienced mountaineers and tourists rapidly 
traveling to high altitude areas such as the Andes, Alps or the Himalaya are affected. 
Gastrointestinal manifestations are cardinal symptoms of AMS.2,3 However, causes and 
pathophysiology of gastrointestinal symptoms of AMS remain elusive, but may include direct 
effects of hypobaric hypoxia on mucosal integrity.4 
Acute mountain sickness is a disease that occurs within the very first days after 
arrival above 2500 meters.2 Typical symptoms include headache, anorexia, nausea, vomiting, 
dizziness and malaise.3 Prevalence of AMS is estimated at 10-25%, but increases to 50-85% 
at elevations above 4500-5500m.5-7 Risk factors for the development of AMS are a past 
medical history of AMS, rapid ascent (≥625m per day), lack of acclimatization, female sex 
and young age.8-10 Gastrointestinal symptoms occur in more than 80% of patients with AMS 
(particularly nausea and vomiting).11 In addition, high rates of peptic ulcer disease have been 
described in native highlanders in the Peruvian Andes.11 Furthermore, upper gastrointestinal 
bleeding from peptic ulcer disease appears to be a frequent problem in high altitude areas.12 
Hypoxia might be an important factor contributing to the development of peptic ulcerations, 
but its exact role remains unclear. In addition, it has yet to be determined whether GI 
symptoms of AMS are based on GI lesions or rather have a pure central nervous system 
origin. 
While AMS usually occurs in healthy individuals, high altitude exposure has been 
recently demonstrated to be associated with flare-ups in patients with inflammatory bowel 
disease (IBD).13,14 Both ascent to above 2000m and commercial flights, which correspond to 
an altitude of 1800-2300m, correlated with a flare of IBD symptoms. However, the link 
between hypoxia and intestinal inflammation appears to be complex. At the molecular level, 
the heterodimeric hypoxia-induced factors HIF1, and HIF2 have opposite functions and work 
as a “switching modulator”, but the dynamic regulation of these factors remains unclear.15 
Chronic activation of HIF2 increases pro-inflammatory cytokines and is associated with 
intestinal injury, while HIF1 activation in colitis leads to a protective response.16,17 Therefore, 
it is uncertain whether HIF activation by short-term hypoxia (such as after rapid ascent to 
high altitude) leads to mucosal inflammation, loss of mucosal integrity or whether this 
system protects against intestinal injury. 
Given these uncertainties, we sought to answer the following questions: i) What is 
the incidence of peptic lesions in healthy mountaineers after rapid ascent to 4559m? ii) Are 
these peptic lesions associated with GI symptoms? iii) What mRNA changes of target genes 




This was a prospective, non-randomized study with healthy mountaineers who 
underwent esophago-gastroduodenoscopy (EGD) at 490m and on two test days (d2 and d4) 
at Capanna Regina Margherita high altitude laboratory in the Alps (4559m, Supplementary 
File 1) upon rapid ascent from 1130m. This analysis represents the endoscopy arm of a 
larger clinical project. Other sub-studies emerging from the project (including studies on 
nutrition and high altitude sickness) have been reported elsewhere.18-20 The study was 
approved by the local ethics committee of the University of Zurich (EK-1677). Written 
informed consent was obtained from all participants before inclusion into the study. 
Study subjects 
Details on subject recruitment and study enrolment have been published 
elsewhere.18,19 Briefly, healthy mountaineers were recruited through alpine magazines and 
using a registry of Air Zermatt (a Swiss air rescue) that included people rescued for high 
altitude disease in the past 5 years. The following exclusion criteria were applied: 1) subjects 
spent more than 3 nights above 2500m within one month before study enrolment; 2) 
subjects had chronic diseases requiring ANY regular medication; 3) subjects adhered to 
dietary restrictions that could not be upheld in the high altitude laboratory (such as gluten-
free, vegetarian or lactose-free diet); and 4) age below 18 or above 65 years. On demand 
intake of drugs such as paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) was 
not an exclusion criterion. 
Data collection 
For the purpose of this study, the following data were collected: 1) demographics 
being sex, age, body mass index (BMI); 2) history of high altitude pulmonary edema 
(HAPE);21 3) oxygen levels using pulse oximetry (Infinity, Dräger, Liebefeld, Switzerland) and 
arterial blood gas analysis (AVL 5 Radiometer, Copenhagen, Denmark); 4) symptoms of AMS 
using two validated instruments, the cerebral-sensitive score of the Environmental Symptom 
Questionnaire (AMS-C) and the Lake Louise scoring system (LLSAS);22 5) gastrointestinal 
symptoms (hunger, dyspepsia) using 10cm visual analogue scales and being reported as 
values ranging from 0 (lowest) to 100 (highest); and 6) laboratory values (lactate, C-reactive 
protein (CRP)). Data were collected at baseline at 490m and days 2 and 4 after ascent to 
4559m. After each endoscopy at 4559m, an ad libitum meal was given to the subjects and 
total calorie intake (kcal) was measured. Medications (dexamethasone, acetaminophen and 
NSAIDs) were started based on predefined criteria (Supplementary Methods). 
Endoscopy 
Subjects underwent transnasal fiberoptic EGD (FG-16V, 5.3mm, Pentax, Tokio, Japan) 
under lidocaine nasal analgesia and 2L oxygen supplement in Zurich (490m) and on two test 
days (d2 and d4) at Capanna Regina Margherita (4559m), where they spent four days after 
rapid ascent from 1130m. For details and endoscopic evaluation, see Supplementary 
Methods.  
Molecular analyses 
mRNA levels of 18 proinflammatory and hypoxia-related genes were measured from 
duodenal biopsies of normally appearing mucosa (Supplementary Methods). 
Statistics 
For all statistical analyses, IBM SPSS software (version 22.0.0, 2013 SPSS Science, 
Chicago, IL) was used. For the purpose of this study, a p-value of <0.05 was considered 
statistically significant. For details see Supplementary Methods.  
 
RESULTS 
Patient demographics and baseline characteristics 
We included a total of 25 patients (mean age 43.8y±9.5, 10 females (40%), mean BMI 
23.8kg/m2±2.2). Eight patients had a previous history of HAPE (32%). One patient took 
NSAIDs at baseline. None of the patients reported intake of PPI. For baseline characteristics, 
see Table 1. Endoscopy was performed in all 25 patients. In one patient, mild reflux 
esophagitis was seen, while in two patients erythema in the stomach was detected. 
Otherwise, EGD was considered to be normal.  
AMS score and medication at 4559m 
AMS-C and LLSAS scores on day 2 (0.56 vs 0, p<0.001, 5 vs 1, p<0.001) and on day 4 
(0.26 vs 0, p=0.002, and 3 vs 1, p=0.003) were significantly higher than at baseline in Zurich. 
No significant differences regarding hunger (baseline 38.2, d2 48.8, d4 49.6) and dyspepsia 
scores (baseline 28.4, d2 39.0, d4 22.2) were detected. Lactate and CRP levels were 
significantly higher at both, day 2 (1.0 vs 0.9 p=0.016 and 2.9 vs 0.7 p<0.001) and day 4 (1.3 
vs 0.9 p=0.009 and 2.8 vs 0.7 p<0.001) compared to baseline. Dexamethasone was applied to 
14 patients. Two patients were on NSAIDs at day 2, and three at day 4, while seven patients 
were put on PPI. Nine patients were taking acetaminophen (Paracetamol) at day 2 and four 
at day 4.  
Endoscopy at 4559m  
19/25 patients underwent endoscopic examination at day 2 and 23/25 at day 4. Two 
patients did not have any follow-up endoscopy at all. The procedure was generally well 
tolerated and safe. No complications occurred despite significantly lower oxygenation: 
Arterial SpO2 was lower at day 2 and day 4 (76.4 vs 97.3% p<0.001 and 81.1 vs 97.3% 
p<0.001) with lower pO2 (39.0 vs 91.5mmHg p<0.001 and 44.3 vs 91.5mmHg p<0.001) and 
O2Hb (76.4 vs 95.0% p<0.001 and 80.5 vs 95.0% p<0.001) compared to baseline (Zurich). The 
findings during d2, d4 follow-up endoscopy are summarized in Figure 1. At day 2, new 
mucosal lesions were seen in 5 patients (2 patients with new lesions in the stomach and 5 
patients with new lesions in the duodenum). Duodenal ulcers developed in 2 patients (1 
patient with three ulcers), no gastric ulcer was detected. At day 4, new mucosal lesions 
(compared to baseline) were seen in 12 patients (9 patients with new lesions in the stomach, 
and 7 patients with new lesions in the duodenum). Gastric ulcers were seen in 3 patients, 
and duodenal ulcers were detected in 3 patients (1 patient with 6 duodenal ulcerations). 
Compared to the first endoscopy at d2, new lesions were seen in 9 patients (gastric lesions in 
7 patients, duodenal lesions in 4 patients). New ulcers developed in 4 patients. Gastric 
lesions were successfully treated with PPI in one patient, while duodenal ulcers showed 
complete remission in another patient. In a third patient receiving PPI between day 2 and 4, 
gastric erosion and duodenal ulcer did not show any response. Taken together, frequency of 
endoscopic lesions increased from 12% (baseline) to 26.3% (d2) and 60.9% (d4), while the 
incidence of peptic ulcer disease rose from 0.0% to 10.5% (d2) and 21.7% (d4). When looking 
at patients without intake of ulcerogenic medication (NSAIDs, dexamethasone) at the time 
of endoscopy, these rates were 8.3% (baseline), 17.6% (d2) and 50% (d4) for endoscopic 
lesions and 0.0% (baseline), 5.9% (d2) and 12.5% (d4) for ulcerations. Figure 2 shows 
representative pictures for the development of erosions and ulcerations in the duodenum at 
4559m.  
Factors associated with development of endoscopic lesions at day 4 
Subjects with peptic lesions on day 4 had significantly lower hunger scores than those 
with normal EGD measured as VAS 0-100 (37.3 vs 67.4, p=0.012, Table 2). Nevertheless, both 
groups were still able to eat a full meal with no significant difference regarding total calorie 
intake (802.1 vs 902.5kcal, n.s.). In addition, lesions were not associated with nausea, 
bloating, pain, fullness, AMS-C/LLSAS scores, oxygenation levels or with the use of 
medications (NSAIDs, dexamethasone, paracetamol). Per our protocol, a significantly larger 
proportion of patients with endoscopic lesions were put on PPI (0 vs 50%, p=0.011). There 
were no differences when only ulcerations (vs. no endoscopic ulceration) were analysed. No 
predictive factor for the development of mucosal lesions was identified using univariate and 
multivariate logistic regression modelling. Results for factors associated with development of 
endoscopic lesions at day 2 are shown in Supplementary Table 1. 
mRNA analyses 
To assess changes in duodenal mRNA levels with regards to development of peptic 
lesions, we excluded all subjects with endoscopically detected lesions at baseline and tested 
mRNA levels for 18 different target genes (Figure 3). mRNA analyses were available for 15 
patients. Of those, 4 patients had a peptic lesion at day 2 and 9 at day 4. Subjects that 
developed peptic lesions at day 2, had higher HIF2A and ICAM1 mRNA levels (Figure 3). 
While subjects without peptic lesions showed a decrease of their HIF2A and ICAM1 mRNA 
levels compared to baseline (fold change 0.63 and 0.66), those with lesions had an increase 
in mRNA levels for both genes (fold change 1.38 and 1.37, p=0.0012 and p=0.011, Figure 4). 
HIF2A increase remained statistically significant after correction for multiple testing (p value 
for significance after Bonferroni correction = 0.0014). There were no differences with 
regards to other factors and cytokines (HIF1A, FOXP3, IL6, IFNγ, NOD2 or TNF).  
 
DISCUSSSION 
The exact causes of gastrointestinal symptoms of AMS are unknown, but may include 
direct effects of hypoxia on mucosal integrity. To assess incidence of peptic lesions, their 
association with GI symptoms, and possible pathogenic mechanisms, we clinically, 
endoscopically and molecularly analyzed healthy mountaineers after rapid ascent to 4559m. 
The main findings of this study are: i) development of peptic lesions including peptic ulcer 
disease is frequently observed within two to four days after fast ascent to high altitude; ii) 
presence of mucosal lesions is associated with lower hunger scores, but no other AMS 
symptoms; and iii) patients with peptic lesions show higher HIF2A and ICAM1 mRNA levels 
compared to patients with normal endoscopy. 
We herein demonstrate, that development of peptic lesions is frequently observed 
within only two to four days after rapid ascent to high altitude. Being clinically relevant, 
these lesions can contribute to gastrointestinal symptoms at high altitude. Indeed, incidence 
of mucosal lesions increased from 12% at baseline to 26.3% at day 2 and 60.9% at day 4 after 
ascent to 4559m. Despite PPI treatment, incidence of endoscopic lesions steadily increased 
over time, which emphasizes on the relative contribution of hypoxia rather than acid 
secretion. In addition, peptic ulcer disease (baseline 0%) was observed in 10.5% at day 2 and 
21.7% at day 4. Thus, one out of five patients developed peptic ulcer disease over this short 
period of time. These findings imply a negative impact of hypobaric hypoxia on mucosal 
integrity resulting from fast ascent to high altitude. This is particularly noteworthy given the 
current approach of treating AMS symptoms with ulcerogenic medication (NSAIDs, 
dexamethasone) that negatively affect mucosal integrity.23,24 Based on our data, these drugs 
should be used with caution. Further, these findings give a rationale for flare-ups in IBD 
patients after flights and ascents to high altitude.13,14 While for various reasons it is not 
feasible to perform colonoscopy in a high altitude laboratory, it is likely that similar lesions 
would be detected in response to hypobaric hypoxia triggering increased IBD symptoms.  
Patients with peptic lesions showed higher HIF2A and ICAM1 mRNA levels compared 
to subjects with normal endoscopy. In contrast, HIF1α mRNA levels were neither in- nor 
decreased. HIF1A and HIF2A are important regulators in response to hypoxia. They appear to 
have non-redundant functions by modulating transcription of an overlapping, but distinct set 
of genes.25 In a simplified model, activation of HIF1 leads to a protective response with 
beneficial effects on epithelial barrier function, while HIF2 triggers pro-inflammatory 
cytokines and epithelial injury.16,17,26-30 Depending on which factor is preferentially activated, 
hypoxia has beneficial or detrimental effects. HIF2A has been shown to correlate with 
increased pro-inflammatory cytokine expression in gastroesophageal reflux disease, while 
HIF1A is repressed in active eosinophilic esophagitis.28,30 Of note, differences in mRNA levels 
between HIF1A and HIF2A were detected after rapid ascent to high altitude in our study. 
HIF2A with its known detrimental effects on mucosal integrity appears to be a contributing 
factor to the development of mucosal lesions in the upper GI tract. Interestingly, the HIF2 
target ICAM1 also showed such upregulation in subjects with endoscopically detected 
lesions. ICAM1 is a transmembranous glycoprotein that binds to integrins expressed on 
inflammatory cells and thereby contributes to leukocyte adhesion, migration and 
stimulation.31,32 As adhesion molecule, it has an important role in lymphocyte trafficking in 
the GI tract.33 ICAM1 has been previously shown to be induced by hypoxia. This hypoxic 
upregulation of ICAM1 can be blocked by siRNA against HIF2A.34 Previous studies have 
shown up-regulation of several pro-inflammatory cytokines in the context of hypoxia, 
beyond ICAM1 expression. However, the interplay between hypoxia and inflammation is 
complex; and several factors may have affected our results. 1) Inflammatory factor 
production in response to hypoxia appears to be time-dependent;35 and 2) short-term and 
chronic hypoxia have been shown to have opposite effects with regards to inflammation 
(pro-vs. anti-inflammatory). The cut-off values used in a previous study to define short-term 
hypoxia was 24 hours, while chronic hypoxia was defined by hypoxia duration of 10 days.36 
Our 2 and 4 days are somewhere in between, which might explain upregulation of some, but 
not all pro-inflammatory cytokines. This could also explain, why we did not detect decreases 
in HIF1A mRNA levels as it has been previously shown in the upper gastrointestinal tract in 
response to hypoxia.28 In addition, findings from in vitro and pressure chamber experiments 
cannot be extrapolated 1:1 to high altitude exposure. Previous high altitude studies have 
further focused on blood samples rather than gastric tissue in particular.37 Based on our 
findings, we speculate that the HIF2-ICAM1 axis contributes to the development of peptic 
ulcer disease per se and to development of flares in IBD patients after flights and ascents to 
high altitude. Drugs selectively targeting HIF2A may be promising agents for these 
conditions.  
Our study has strengths and limitations. To the best of our knowledge, this is the first 
time that upper endoscopy was performed after fast ascent to a high altitude laboratory. We 
herein show that unsedated transnasal EGD at 4559m is feasible and safe. Repetitive 
endoscopies made it possible to assess the dynamic development of peptic lesions and 
ulcers over time. This is particularly important given the presence of endoscopic 
abnormalities in healthy controls, which might be as high as 18%.38 One major limitation is 
the fact that only duodenal samples were collected and that the biopsies were not taken 
from the endoscopic lesion due to safety concerns at 4559m. However, since subjects were 
all healthy volunteers, we assume that hypoxia was evenly distributed throughout the 
stomach and duodenum. Due to logistic restrictions at 4559m, biopsies were immediately 
snap frozen in liquid nitrogen and therefore not accessible for histological evaluation. 
Blinding of endoscopists to patients symptoms and central video reading was not feasible 
given restrictions in terms of equipment and limited space at 4559m. Intake of 
dexamethasone and NSAIDs are potential confounders. However, when looking at patients 
without the intake of ulcerogenic medication at the time of endoscopy, similar increase in 
rates of endoscopic lesions and peptic ulcer disease were seen over time. In addition, 
dexamethasone was not started before evening of day 2 (=after follow-up endoscopy). To 
further limit the counfounding impact of ulcerogenic medications, we only looked at patients 
with development of peptic lesions at day 2 for our mRNA analyses (before dexamethasone 
intake). Our study relied on mRNA levels only and did not include analyses of protein 
expression. Therefore, we cannot exclude that HIF1A protein expression was affected by 
protein degradation as previously described.28 Finally we cannot exclude that heavy exercise 
might have affected gastrointestinal perfusion and thereby our endoscopic findings. 
However, this is less likely the case particularly for the second follow-up endoscopy. 
In conclusion, fast ascent to high altitude results in rapid onset of mucosal lesions 
(including ulcer disease) in a high proportion of otherwise healthy subjects. These lesions 
were associated with reduced sensation of hunger and are, therefore, clinically meaningful 
in the presentation of AMS. HIF2A-induced ICAM1 upregulation might be a pathogenic factor 
for hypoxia-induced peptic lesions and this mechanism may also underlie the occurrence of 
















Table 1: Patient demographics and baseline characteristics at 490m 
Table 2: Comparison between patients with vs. without endoscopic lesions at day 4 
Figure 1: Percentage of patients with endoscopic lesions at baseline and day 2, 4 after rapid 
ascent to 4559m. Frequency of mucosal lesions increases from 12% (baseline) to 26.3% (d2) 
and 60.9% (d4). The incidence of peptic ulcer disease rises from 0.0% to 10.5% (d2) and 
21.7% (d4). Dark gray indicates ulcers, while light gray indicates mucosal lesions. 
Figure 2: Representative endoscopic pictures showing development of erosions and 
ulcerations in the duodenum at 4559m. Arrows point on erosion (picture on the left) and 
ulceration (two pictures on the right). 
Figure 3: Heatmap for mRNA expression levels (compared to baseline) in patients with vs. 
without endoscopic lesions. Numbers indicate fold change. Green color indicates 
upregulation, red color means downregulation. 
Figure 4: HIF2A and ICAM1 mRNA expression levels (compared to baseline) in patients with 
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